Trial Profile
Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Jun 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Meningioma
- Focus Therapeutic Use
- 10 May 2023 Planned End Date changed from 1 Sep 2025 to 1 Mar 2025.
- 29 Jul 2021 Status changed from recruiting to active, no longer recruiting.
- 04 Sep 2020 Planned End Date changed from 31 Mar 2025 to 1 Sep 2025.